New hep C drugs to be listed on PBS

Two long-awaited new drugs for hepatitis C are set to receive the nod for public funding, in a move predicted to “transform the lives” of Australians living with the virus.

Telaprevir (Incivo) and boceprevir (Victrelis), the first in a new class of HCV-protease inhibitors, have been shown to increase cure rates and shorten treatment duration in genotype 1 hepatitis C.

Their high cost had been a stumbling block for PBS listing, but it is now understood they will be given the green